Impact of Breast Cancer Screening on 10-Year Net Survival in Canadian Women Age 40-49 Years.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
10 Oct 2023
Historique:
pubmed: 4 8 2023
medline: 4 8 2023
entrez: 4 8 2023
Statut: ppublish

Résumé

In Canada, some provincial/territorial mammography screening programs include women age 40-49 years, whereas others do not. This study examines the impact of this dichotomy on the 10-year breast cancer (BC) net survival (NS) among women age 40-49 years and 50-59 years at diagnosis. Using the Canadian Cancer Registry data record linked to death information, we evaluated the cohort of Canadian women age 40-49 years and 50-59 years diagnosed with BC from 2002 to 2007. We compared 10-year NS estimates in the jurisdictions with organized screening programs that included women age 40-49 years, designated as screeners (Northwest Territories, British Columbia, Alberta, Nova Scotia, and Prince Edward Island), with comparator programs that did not (Yukon, Manitoba, Saskatchewan, Ontario, Quebec, New Brunswick, and Newfoundland and Labrador). BC was the primary cause of 10-year mortality in women age 40-49 years diagnosed with BC (90.7% of deaths). Among these women, the 10-year NS for screeners (84.8%; 95% CI, 83.8 to 85.8) was 1.9 percentage points (pp) higher than that for comparators (82.9%; 95% CI, 82.3 to 83.5; Screening programs that included women in their 40s were associated with a significantly higher BC 10-year NS in women age 40-49 years, but not an increased rate of BC diagnosis. These results may inform screening guidelines for women age 40-49 years.

Identifiants

pubmed: 37540825
doi: 10.1200/JCO.23.00348
pmc: PMC10564321
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4669-4677

Références

J Natl Cancer Inst. 2004 Dec 15;96(24):1832-9
pubmed: 15601639
Curr Oncol. 2022 May 30;29(6):3894-3910
pubmed: 35735420
J Intern Med. 2006 Aug;260(2):103-17
pubmed: 16882274
Int J Cancer. 2014 Oct 15;135(8):1774-82
pubmed: 24945976
Med J Aust. 2020 Mar;212(4):163-168
pubmed: 31858624
Mol Genet Genomic Med. 2020 Feb;8(2):e1070
pubmed: 31782267
Cancer. 2020 Jul 1;126(13):2971-2979
pubmed: 32390151
Radiology. 2018 May;287(2):391-397
pubmed: 29267146
Lancet. 1985 Apr 13;1(8433):829-32
pubmed: 2858707
Health Rep. 2023 Jan 18;34(1):3-15
pubmed: 36716075
J Med Screen. 2012;19 Suppl 1:42-56
pubmed: 22972810
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
JAMA. 2015 Oct 20;314(15):1599-614
pubmed: 26501536
Cancer. 2011 Feb 15;117(4):714-22
pubmed: 20882563
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):187-97
pubmed: 25417232
Stat Med. 2000 Jul 15;19(13):1729-40
pubmed: 10861774
Obstet Gynecol Clin North Am. 2011 Sep;38(3):425-40
pubmed: 21961711
Health Rep. 2021 Sep 15;32(9):14-26
pubmed: 34523870
Lancet Oncol. 2021 Aug;22(8):1139-1150
pubmed: 34339645
Breast Cancer Res Treat. 2021 Aug;189(1):203-212
pubmed: 33893907
Am Health Drug Benefits. 2016 Feb;9(1):23-32
pubmed: 27066193
Breast. 2022 Aug;64:85-99
pubmed: 35636342
Eur J Cancer. 2022 Sep;173:1-9
pubmed: 35839596
Health Rep. 2015 Dec;26(12):3-8
pubmed: 26676233
Cancer Epidemiol. 2010 Oct;34(5):550-5
pubmed: 20638928
Ann Intern Med. 2016 Feb 16;164(4):244-55
pubmed: 26756588
J Natl Compr Canc Netw. 2023 Jun;21(6):594-608
pubmed: 37308117
J Natl Cancer Inst. 2014 Oct 01;106(11):
pubmed: 25274578
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):145-86
pubmed: 25417231
Lancet Oncol. 2016 Jan;17(1):109-14
pubmed: 26655422
AJR Am J Roentgenol. 2018 Feb;210(2):264-270
pubmed: 29064760
Biometrics. 2012 Mar;68(1):113-20
pubmed: 21689081
Cancer Causes Control. 2013 Mar;24(3):505-15
pubmed: 23296456
Breast Cancer Res. 2020 May 27;22(1):53
pubmed: 32460821
Prev Med. 2016 Sep;90:66-71
pubmed: 27374944
JAMA Oncol. 2015 Nov;1(8):1069-77
pubmed: 26501844
Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1699-705
pubmed: 19505902
CMAJ. 2011 Nov 22;183(17):1991-2001
pubmed: 22106103
N Engl J Med. 2015 Jun 11;372(24):2353-8
pubmed: 26039523
J Natl Cancer Inst. 2021 Jul 1;113(7):909-916
pubmed: 33169794
CMAJ. 2018 Dec 10;190(49):E1441-E1451
pubmed: 30530611
Curr Oncol. 2022 Aug 09;29(8):5627-5643
pubmed: 36005182
CMAJ. 2022 May 2;194(17):E601-E607
pubmed: 35500919
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
J Med Screen. 2004;11(3):126-9
pubmed: 15333270

Auteurs

Anna N Wilkinson (AN)

Department of Family Medicine, University of Ottawa.

Larry F Ellison (LF)

Centre for Population Health Data at Statistics Canada, Government of Canada, Ottawa, Canada.

Jean-Michel Billette (JM)

Centre for Population Health Data at Statistics Canada, Government of Canada, Ottawa, Canada.

Jean M Seely (JM)

University of Ottawa, Department of Radiology, Ottawa Hospital Research Institute, Ottawa, Canada.

Classifications MeSH